<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03737357</url>
  </required_header>
  <id_info>
    <org_study_id>CR 2017-05</org_study_id>
    <nct_id>NCT03737357</nct_id>
  </id_info>
  <brief_title>Dental Implants With a SLActive® vs. SLA® Surface</brief_title>
  <official_title>A Randomized Controlled Study to Assess Intra-patient Clinical Performance of Dental Implants With a SLActive® vs. SLA® Surface</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Straumann AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Straumann AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This post-market study is to show that dental implants with a SLActive® surface (SLActive®&#xD;
      implants) show non-inferior clinical performance compared to dental implants with a SLA®&#xD;
      surface (SLA® implants). The primary hypothesis is that 12 months after implant loading, the&#xD;
      bone loss around the SLActive® implants will not be appreciably greater than around the SLA®&#xD;
      implants.&#xD;
&#xD;
      The occurrence of adverse events and device deficiencies will also be recorded to confirm&#xD;
      once more the safety of the Straumann® Bone Level Tapered (BLT), Roxolid® implant.&#xD;
&#xD;
      Osseointegration and anti-inflammatory potential of SLActive® implants will be evaluated in&#xD;
      the study as secondary endpoints.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, single-blinded, randomized, paired sample, multi-center clinical&#xD;
      study. Eight visits per patient are scheduled in this study. The final analysis will be&#xD;
      conducted after all patients completed the 12-month visit.&#xD;
&#xD;
      The study devices are CE- (Conformité Européenne, meaning European Conformity) marked&#xD;
      products and used within their intended use.&#xD;
&#xD;
      Two centers in Spain will participate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 9, 2019</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone Level Change</measure>
    <time_frame>12 months after implant loading</time_frame>
    <description>Bone level change at 12 months after implant loading</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of adverse device effects and device deficiencies that could have led to a serious adverse device effect</measure>
    <time_frame>12 months after implant loading</time_frame>
    <description>Occurrence of adverse device effects and device deficiencies that could have led to a serious adverse device effect</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone Level Change</measure>
    <time_frame>between implant placement and loading and between loading and 12 months after implant loading</time_frame>
    <description>Bone Level Change between implant placement and loading and between loading and 12 months after implant loading</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in inflammatory and anti-inflammatory biomarkers concentrations</measure>
    <time_frame>30 days after implant placement</time_frame>
    <description>Change in inflammatory and anti-inflammatory biomarkers (IL-10, IL-4, IL-6, IL-1beta, TNF-alpha, IL-2) concentrations in gingival crevicular fluid samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in osseointegration biomarkers concentrations</measure>
    <time_frame>between day 7 and 8 weeks after implant placement</time_frame>
    <description>Change in osseointegration biomarkers ( VEGF, osteocalcin (OCN), osteopontin (OPN)) concentrations in gingival crevicular fluid samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implant survival</measure>
    <time_frame>12 months after implant loading</time_frame>
    <description>Implant survival at 12 months after implant loading</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Partially Edentulous Patients</condition>
  <arm_group>
    <arm_group_label>SLActive® implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SLA® implant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SLActive® implant</intervention_name>
    <description>One study test (SLActive® surface) (and simultaneously, in a split-mouth design one study control (SLA® surface) implant (Bone Level Tapered, Roxolid®)) will be placed in two different quadrants of partially edentulous patients. The implants will be placed at premolars, molars and canine positions in the mandible and maxilla (healed extraction sites). Implants will be restored with a single crown or splinted restorations 8 weeks after implant placement.</description>
    <arm_group_label>SLActive® implant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SLA® implant</intervention_name>
    <description>One study test (SLActive® surface) (and simultaneously, in a split-mouth design one study control (SLA® surface) implant (Bone Level Tapered, Roxolid®)) will be placed in two different quadrants of partially edentulous patients. The implants will be placed at premolars, molars and canine positions in the mandible and maxilla (healed extraction sites). Implants will be restored with a single crown or splinted restorations 8 weeks after implant placement.</description>
    <arm_group_label>SLA® implant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  males and females, at least 18 years old&#xD;
&#xD;
          -  partially edentulous patients in need of two or more dental implants (canine to&#xD;
             molars) placed in two different quadrants in healed sites (3 months post extraction)&#xD;
&#xD;
          -  subject must have voluntarily signed the informed consent, is willing and able to&#xD;
             attend scheduled follow-up visits, and agrees that the encoded data will be collected&#xD;
             and analyzed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  any contraindications for oral surgical procedures&#xD;
&#xD;
          -  dental implant placement contraindicated according to Instructions for Use (IFU)&#xD;
&#xD;
          -  subjects with inadequate oral hygiene (FMPS ≥ 20%)&#xD;
&#xD;
          -  subjects who are currently heavy smokers (defined &gt;10 cigarettes per day or &gt;1 cigar&#xD;
             per day) or who use chewing tobacco&#xD;
&#xD;
          -  subjects with drug or alcohol abuse&#xD;
&#xD;
          -  patients requiring soft tissue and bone grafting procedures&#xD;
&#xD;
          -  inadequate bone volume&#xD;
&#xD;
          -  severe bruxism or clenching habits&#xD;
&#xD;
          -  women who are pregnant or planning to become pregnant at any point during the study&#xD;
             duration.&#xD;
&#xD;
          -  patients who have systemic factors that could interfere with the healing process of&#xD;
             either bone or soft tissue or the osseointegration process (e.g. bone metabolism&#xD;
             disturbances, uncontrolled diabetes mellitus, anticoagulation drugs/ hemorrhagic&#xD;
             diatheses)&#xD;
&#xD;
          -  patients with local factors that could interfere with the healing process, such as&#xD;
             untreated periodontal diseases, acute infection of implant site, temporomandibular&#xD;
             joint disorders, treatable pathologic diseases of the jaw and changes in the oral&#xD;
             mucosa)&#xD;
&#xD;
          -  conditions or circumstances, in the opinion of the investigator, which would prevent&#xD;
             completion of study participation or interfere with analysis of study results, such as&#xD;
             history of non-compliance, or unreliability.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mariano Sanz, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor and Chairman of Periodontology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan Blanco-Carrión, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor in Periodontology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universidad Complutense</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidad de Santiago de Compostela</name>
      <address>
        <city>Santiago De Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 25, 2018</study_first_submitted>
  <study_first_submitted_qc>November 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2018</study_first_posted>
  <last_update_submitted>July 30, 2021</last_update_submitted>
  <last_update_submitted_qc>July 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dental implants</keyword>
  <keyword>SLActive® surface</keyword>
  <keyword>biomarkers</keyword>
  <keyword>BLT implant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mouth, Edentulous</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

